
    
      This study is a multicenter, randomized, open-label, dose finding study of VERU-100 to attain
      and maintain serum total testosterone levels within castrate range (<50ng/dL) in men with
      advanced prostate cancer. Stage 1 of the study will assess the effect of 150 mg of VERU-100.
      Stage 2 will further assess the efficacy of the effective doses of VERU-100 in an expanded
      patient population.
    
  